Affiliation:
1. R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine; 45 Vasyl’kovskaya St., Kyiv 03022
Abstract
Multiple myeloma originating from clonal proliferation of plasma cells in the bone marrow is one of the most prevalent hematological malignancies worldwide. The pathogenetic mechanisms of multiple myeloma are far from being elucidated. Nevertheless, it is known that the adipocytes as the prevalent cellular component of bone marrow microenvironment contribute significantly to multiple myeloma growth and progression. The review discloses the recent data on the interactions between bone marrow adipocytes and myeloma cells, hematopoietic stemcells, hematopoietic progenitor cells, mesenchimal stem cells, osteoblasts, osteoclasts, endothelial cells, and cells of immune system. Also, the review places special emphasis on bone marrow adipocyte-produced adipokines, growth factors, cytokines, chemokines, and fatty acids providing the conditions for the preferential growth and migration of malignant plasma cells and contributing to hematopoiesis supression, bone tissue resorption, angiogenesis activation and immunosuppression.
Publisher
Publishing House ABV Press
Reference143 articles.
1. Votyakova O.M., Demina E.A. Mnozhestvennaya mieloma. V kn.: Klinicheskaya onkogematologiya: rukovodstvo dlya vrachei. Pod red. M.A. Volkovoi. M.: Meditsina, 2001. S. 423–448. [Votyakova O.M., Demina E.A. Multiple myeloma. In: Clinical Oncohematology: physicians guide. Ed.: M.A. Volkova. Moscow: Meditsina, 2001. Pp. 423–448. (In Russ.)].
2. Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538–48. DOI: 10.1016/S1470-2045(14)70442-5. PMID: 25439696.
3. Bessmel'tsev S.S. Mnozhestvennaya mieloma (lektsiya). Vestnik gematologii 2014;X(3):6–39. [Bessmeltsev S.S. Multiple myeloma (lecture). Vestnik gematologii = Bulletin of Hematology 2014;X(3):6–39. (In Russ.)].
4. Podar K., Tai Y.T., Hideshima T. et al. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 2009;14(1): 99–127. DOI: 10.1517/14728210802676278. PMID: 19249983.
5. SEER Cancer Statistics Review, 1975–2015. National Cancer Institute. Eds.: M.D. Bethesda, A.M. Noone, N. Howlader et al. Section 18. Myeloma. Available at: https://seer.cancer.gov/ csr/1975_2015/.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献